News & Events

2010

Showing page 1 - 5 of 6

Sagentia chosen to drive development of T2 Biosystems’ next generation medical diagnostic products

Sagentia announced today it has been hired by T2 Biosystems to work on the development of T2 Biosystems’ next generation of medical diagnostic products to improve medical care worldwide.
Date: 14 December 2010

Effective treatment of respiratory disease could be limited by a one-size-fits-all approach to inhaler design, research reveals

To challenge the current 'one-size-fits-all' approach to inhaler design and manufacture, researchers at Sagentia have released findings around the correlation between the effectiveness of dry powder inhalers (DPIs) and a person's unique physiological characteristics. The research, being presented at the annual Drug Delivery to the Lungs conference, has important implications for the treatment of asthma and chronic obstructive pulmonary disease (COPD).
Date: 10 December 2010

The Gen Autumn 2010

In this edition of The Gen our feature articles consider the ongoing debate around medical device reuse and how new usability standards need to be integrated into product design and development. Elsewhere we explore the significant savings that can be made through patent portfolio optimisation and highlight how our innovative application of science combined with sound engineering led to a breakthrough product that helped our client maintain market differentiation.
Date: 25 November 2010

Sagentia announces expansion of US operations through new Cambridge office

Sagentia and the Massachusetts Life Sciences Center announced today the recent opening of Sagentia’s new Cambridge, Massachusetts location. The company has decided to concentrate and expand its U.S. presence at One Broadway in Cambridge, Massachusetts.
Date: 22 November 2010

Tune in to compliance

Sagentia announces the launch of ‘Sensohaler’, a novel technology for inhaler compliance monitoring that offers significant improvement to the usability of inhaler products, benefiting the patient and creating significant cost savings over the treatment period.
Date: 26 April 2010 Showing page 1 - 5 of 6